Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations

Ahmet Yilmaz, Nehad Mohamed, Kara A. Patterson, Yan Tang, Konstantin Shilo, Miguel A. Villalona-Calero, Michael E. Davis, Xiao-Ping Zhou, Wendy Frankel, Gregory A. Otterson and Weiqiang Zhao
Additional contact information
Ahmet Yilmaz: Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
Nehad Mohamed: Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
Kara A. Patterson: Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
Yan Tang: Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
Konstantin Shilo: Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
Miguel A. Villalona-Calero: Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
Michael E. Davis: Department of Animal Sciences, The Ohio State University, Columbus, OH 43210, USA
Xiao-Ping Zhou: Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
Wendy Frankel: Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
Gregory A. Otterson: Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
Weiqiang Zhao: Department of Pathology, The Ohio State University, Columbus, OH 43210, USA

IJERPH, 2014, vol. 11, issue 9, 1-16

Abstract: Lung cancer (LC) and colorectal cancer (CRC) are the first and second deadliest types of cancer worldwide. EGFR-based therapy has been used in the treatment of these cancers with variable success. Presence of mutations in the KRAS driver oncogene, possibly induced by environmental factors such as carcinogens in diet and cigarette smoke, may confer worse prognosis and resistance to treatment for reasons not fully understood. Data on possible associations between KRAS mutational status and clinical and metabolic parameters, which may help in clinical management, as well as in identifying risk factors for developing these cancers, are limited in the current literature. We sequenced the KRAS gene and investigated the associations of variations in 108 patients with non-small cell lung carcinoma (NSCLC), the most common form of LC, and in 116 patients with CRC. All of the mutations originated from the guanosine nucleotide and over half of all transversions in NSCLC and CRC were c.34 G>T and c.35 G>T, respectively. c.35 G>A was the most frequent type of transition in both cancers. Excluding smoking, the clinical and metabolic parameters in patients carrying mutant and wild type KRAS were similar except that the CRC patients with transversion mutations were 8.6 years younger than those carrying the transitions ( P < 0.01). Dyslipidemia, hypertension, family cancer history, and age of diagnosis older than 60 years were more frequent in NSCLC than CRC ( P ? 0.04). These results suggest that most of the clinical and metabolic parameters investigated in this study are probably not associated with the more aggressive phenotype and differences in response to EGFR-based treatment previously reported in patients with KRAS mutations. However, the increased rates of abnormal metabolic parameters in patients with NSCLC in comparison to CRC indicate that these parameters may be more important in the management of NSCLC. CRC patients carrying transition mutations are older than those carrying transversions, suggesting that age may determine the type of KRAS mutation in CRC patients.

Keywords: KRAS; non-small cell lung carcinoma; colorectal cancer; transition; transversion (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2014
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/11/9/8645/pdf (application/pdf)
https://www.mdpi.com/1660-4601/11/9/8645/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:11:y:2014:i:9:p:8645-8660:d:39570

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().